Clinical trials: mCRPC, open to volunteers
mCRPC
AXT-1003 Combination With Enzalutamide in Participants With mCRPC
The purpose of this study is to evaluate the efficacy, and safety of AXT-1003 combined with Enzalutamide in subjects with advanced prostate cancer.
- Trial name
- NCT07897071
- Testing
- AXT-1003, Enzalutamide
- Where
- 4 sites in China
- Volunteers
- 105 people
- Sponsor
- Axter Therapeutics (Beijing) Co., Ltd
Metastatic Castration-resistant Prostate Cancer
Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer
This research study is for people with metastatic castrate-resistant prostate cancer (mCRPC). Zanzalintinib is a new drug that shows activity in mCRPC with soft tissue or visceral metastases who have progressed on prior…
- Trial name
- NCT07608718
- Testing
- Zanzalintinib
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Pedro Barata, MD, MSc
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
- Trial name
- NCT05413850
- Testing
- Lutetium (177Lu) rhPSMA-10.1 Injection, 18F-rhPSMA-7.3 injection (in phase 1 only)
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 82 people
- Sponsor
- Blue Earth Therapeutics Ltd